TABLE 3.
Bone tissue- and fluid-to-plasma concentration ratios of afabicin desphosphono at the time of resection after the third oral dose of afabicin in patients undergoing hip replacement surgeryf
| Compartment | Concn at: |
||||
|---|---|---|---|---|---|
| 2 h after 3rd dose (n = 4) | 4 h after 3rd dose (n = 3) | 6 h after 3rd dose (n = 4) | 12 h after 3rd dose (n = 3) | Mean (n = 14) | |
| Cortical bone (ng/g) | 0.15 (18.6)b | 0.27 (28.7) | 0.20 (42.7)b | 0.25 (17.4) | 0.21 (34.2)d |
| Cancellous bone (ng/g) | 0.39 (25.4)b | 0.45 (18.7) | 0.38 (17.0)b | 0.43 (20.9) | 0.41 (19.3)d |
| Bone marrow (ng/g) | 0.30 (53.1) | 0.37 (14.0) | 0.31 (32.4)b | 0.43 (20.0) | 0.35 (34.0)e |
| Soft tissue (ng/g) | 0.32 (34.2) | 0.30 (31.9) | 0.34 (30.0)b | 0.35 (32.4) | 0.33 (28.5)e |
| Synovial fluid (ng/ml) | 0.44 (17.4)a | 0.57 (9.6)a | 0.53 (4.5)a | 0.64 (26.3)a | 0.54 (19.3)c |
a
Data are for 2 observations.
b
Data are for 3 observations.
c
Data are for 8 observations.
d
Data are for 12 observations.
e
Data are for 13 observations.
f
Afabicin was administered at 240 mg q12h. Results are geometric means (geometric CV [in percent]) by time point and overall by tissue or fluid; n, number of patients. Unless indicated otherwise in a footnote, the data are for a number of observations equal to the number of patients.